Nucala (mepolizumab) receives positive CHMP opinion for treatment of chronic obstructive pulmonary disease (COPD)
Nucala : une avancée prometteuse pour la BPCO ! Basé sur l'essai MATINEE de phase III, ce traitement réduit significativement les exacerbations chez les patients sous triple thérapie inhalée, comparé au placebo. Seul biologique mensuel étudié sur une vaste population éosinophilique, il pourrait offrir une nouvelle option aux millions d'Européens non contrôlés malgré un taux élevé d'éosinophiles.
GSK - 13 Déc 2025
Positive opinion based on MATINEE phase III trial showing significant reduction in COPD exacerbations versus placebo in addition to inhaled triple therapy
Nucala is the only monthly biologic studied in a wide COPD population with an eosinophilic phenotype
Nucala could offer a new option to millions of Europeans who remain uncontrolled on inhaled triple therapy and have a raised blood eosinophil count
Nucala is the only monthly biologic studied in a wide COPD population with an eosinophilic phenotype
Nucala could offer a new option to millions of Europeans who remain uncontrolled on inhaled triple therapy and have a raised blood eosinophil count
